Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain

Journal of Pain and Symptom Management

Volumn 22, Issue 1, 2001, Pages 575-583

  Payne, Richard ^a,j   Coluzzi, Paul ^b   Hart, Lowell ^c   Simmonds, Mary ^d   Lyss, Alan ^e   Rauck, Richard ^f   Berris, Robert ^g   Busch, Michael A ^h   Nordbrook, Earl ^h   Loseth, Diane B ^a   Portenoy, Russell K ⁱ  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Breast Care Center   (United States)

^c Florida Cancer Specialists   (United States)

^d Cowley Associates ^*  (United States)

^e MISSOURI BAPTIST MEDICAL CENTER   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g ROCKY MOUNTAIN CANCER CENTERS   (United States)

^h Anesta Corporation   (United States)

ⁱ BETH ISRAEL MEDICAL CENTER   (United States)

^j Memorial Hospital   (United States)

more..

Author keywords

Cancer pain; Long term therapy; Oral transmucosal fentanyl; Side effects

Indexed keywords

FENTANYL; FENTANYL CITRATE; HYDROMORPHONE; MORPHINE; OXYCODONE;

ADULT; AGED; ARTICLE; BREAKTHROUGH PAIN; CANCER PAIN; CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MOUTH MUCOSA; MULTICENTER STUDY; NAUSEA; OUTCOMES RESEARCH; PATIENT SATISFACTION; SOMNOLENCE; SUSTAINED RELEASE PREPARATION; UNIVERSITY HOSPITAL; VERTIGO; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANALGESICS, OPIOID; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PAIN; PATIENT SATISFACTION; TIME FACTORS;

EID: 0034965392     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(01)00306-2     Document Type: Article

References (14)

1. Character of terminal illness in the advanced cancer patient; pain and other symptoms in the last 4 weeks of life
2. Pain in ambulatory patients with lung or colon cancer; prevalence, characteristics and impact
3. Pain and its treatment in outpatients with metastatic cancer
4. Breakthrough pain; definition, prevalence and characteristics
5. Oral transmucosal fentanyl citrate; randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients
6. Dose titration, multicenter study of oral transmuscosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain
7. Oral transmuscosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients; a controlled dose titration study
8. Absorption and bioavailability of oral transmucosal fentanyl citrate
9. Pharmacokinetics of fentanyl during constant rate IV fusion for the relief of pain after surgery
10. Oral transmucosal fentanyl citrate (OTFC) compared with IV morphine for acute pain in patients following abdominal surgery
11. Intranasal fentanyl titration for postoperative pain management in an unselected population
12. Patient-controlled intranasal analgesia; a method for noninvasive postoperative pain management